GlassScriptPhysician profile
Martin Cadeiras
NPI 1013152768
$5,154.44
in general payments reported to CMS, 2019-2025
22 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,610 · 2020: $207 · 2021: $751 · 2022: $1,058 · 2023: $538 · 2024: $518 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,056.27 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $727.04 | 2019-2023 | |
| Abiomed | $711.68 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $541.03 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $297.60 | 2019-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $243.88 | 2019-2024 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $219.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.22 | 2025 | Jardiance |
| Pfizer INC. | $180.89 | 2019-2024 | |
| Novo Nordisk INC | $124.49 | 2020 | |
| Portola Pharmaceuticals, LLC | $123.89 | 2019 | |
| Getinge USA Sales, LLC | $123.84 | 2019 | |
| Cvrx, INC. | $115.11 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $105.25 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $96.00 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $92.83 | 2019 | |
| Akcea Therapeutics, INC. | $83.97 | 2019 | |
| Impulse Dynamics (USA) INC. | $42.37 | 2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $35.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $18.59 | 2019 | |
| Recor Medical INC | $18.05 | 2024 | Paradise Renal Denervation System |
| Amgen INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Cadeiras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.